Filing Flows › Atara Biotherapeutics (ATRA) › Q2 2026 › vs Q2 2025
Atara Biotherapeutics (ATRA) Q2 2026 vs Q2 2025 (year over year)
Atara Biotherapeutics's revenue fell $16.9M (-96%) from $17.6M in Q2 2025 to $630K in Q2 2026.
Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%, net loss $4.8M, operating cash flow −$3.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $630K | $17.6M | −$16.9M | -96% |
| Net loss | $4.8M | −$2.4M | $7.2M | — |
| Costs & expenses | $5.5M | $17.6M | −$12.1M | -69% |
| Operating costs | $5.3M | $14.4M | −$9.0M | -63% |
| Interest & other, net | $113K | $807K | −$694K | -86% |
| Income tax | $1K | $3K | −$2K | -67% |
| Research & development | $1.3M | $7.3M | −$6.0M | -82% |
| General & admin | $3.8M | $6.5M | −$2.7M | -41% |
| Other operating costs | $191K | $554K | −$363K | -66% |
| Operating cash sources | $4.8M | −$2.4M | $7.2M | — |
| Depreciation & amortization | $14K | $236K | −$222K | -94% |
| Share-based compensation | $394K | $2.8M | −$2.4M | -86% |
| Working capital & other | $1.1M | −$12.7M | $13.8M | — |
| Cash used in operations | $3.3M | $7.3M | −$4.0M | -54% |
| Net loss absorbed | $4.8M | −$2.4M | $7.2M | — |
Questions
How much did Atara Biotherapeutics's revenue grow year over year in Q2 2026?
Atara Biotherapeutics's revenue fell $16.9M (-96%) from $17.6M in Q2 2025 to $630K in Q2 2026.